25 June 2021 - EMA’s CHMP recommended eight medicines for approval at its June 2021 meeting.

The Committee recommended granting a conditional marketing authorisation for Abecma (idecabtagene vicleucel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three previous therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has worsened since receiving the last treatment.

Read EMA press release